Second Launch For Rozlytrek, In Japan, But Sales Prospects Limited
Entrectinib becomes first tumor-agnostic drug to be launched in Japan, its second market globally after the US, but commercial prospects will be limited given the highly specific patient population.
You may also be interested in...
Latest Japan Approvals Include World-First For Pabinafusp
A new batch of marketing authorizations in Japan includes new therapies for high-need cancer indications and rare diseases, and the first nod worldwide for a novel lysosomal disorder treatment that can address serious CNS symptoms.
ASCO 2020: Roche Highlights TIGIT As Tecentriq Bags Another Approval
The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.
EU Approval Nod Possible For Novartis, Gilead/Galapagos, and Janssen
The May meeting of the European Medicines Agency’s drug evaluation committee, the CHMP, is under way. Decisions are due on whether eight marketing approval applications should be approved for marketing in the EU.